Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages

  Marazuela, M ^a   Paniagua, A E ^a   Gahete, M D ^e   Lucas, T ^c   Alvarez Escola C ^b   Manzanares, R ^a   Cameselle Teijeiro, J ^d   Luque Ramirez, M ^a   Luque, R M ^e   Fernandez Rodriguez, E ^d   Castano J P ^e   Bernabeu, I ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Santiago University Clinical Hospital   (Spain)

^e UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER TISSUE; CLINICAL EXAMINATION; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DRUG CARCINOGENICITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPAIN; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; UNIVERSITY HOSPITAL;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PITUITARY GLAND; RECEPTORS, SOMATOTROPIN; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; YOUNG ADULT;

EID: 79951716376     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1742     Document Type: Article

References (49)

1. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759 (Pubitemid 33152999)
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177 (Pubitemid 30211048)
3. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723 (Pubitemid 32374928)
4. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646 (Pubitemid 35191626)
5. Frohman LA, Bonert V 2007 Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 10:283-289
6. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691 (Pubitemid 41415476)
7. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
8. Buhk JH, Jung S, Psychogios MN, Göricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Brückmann H, Dörfler A, Jordan M, Buchfelder M, Knauth M 2010 Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 95:552-558
9. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ 2009 Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161:27-35
10. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF 2008 Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159:517-523
11. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
12. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82 (Pubitemid 46553905)
13. Trainer PJ 2009 ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19-S24
14. Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, De Marinis L, Klibanski A 2009 Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest 32:924-933
15. Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ 2009 Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol Oxf 71:86-91
16. Drake WM, Berney DM, Kovacs K, Monson JP 2005 Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Eur J Endocrinol 153:203-205 (Pubitemid 41167476)
17. Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brubach K, Stalla GK, Strasburger CJ 2009 The German ACROSTUDY: past and present. Eur J Endocrinol 161(Suppl 1):S3-S10
18. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529 (Pubitemid 32273628)
19. Bernabeu I, Cameselle-Teijeiro J, Casanueva FF, Marazuela M 2009 Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. Eur J Endocrinol 160:869-872
20. Marazuela M, Lucas T, Alvarez-Escolá C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramírez M, Halperin I, Casanueva FF, Bernabeu I 2009 Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160:535-542
21. Marazuela M, Daudén E, Ocón E, Moure D, Nattero L 2007 Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann Intern Med 147:741-743 (Pubitemid 351664476)
22. Bernabeu I, Alvarez-EscoláC, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M 2010 The exon 3-deleted growth hormone receptor Is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95:222-229
23. Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez-EscoláC, Luque-Ramírez M, Fernandez-Rodriguez E, Paniagua AE, Quinteiro C, Casanueva FF 2010 Pegvisomant-induced liver Injury is related to the UGT1A*28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab 95:2147-2154
24. Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65-74 (Pubitemid 46553904)
25. Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A, Castaño JP 2010 A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 95:2497-2502
26. Di Chiro G, Nelson KB 1962 The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med 87:989-1008
27. Lundin P, Pedersen F 1992 Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16:519-528
28. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW 2001 Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86:478-481 (Pubitemid 32207445)
29. Besser GM, Burman P, Daly AF 2005 Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 153:187-193 (Pubitemid 41167474)
30. Parkinson C, Burman P, Messig M, Trainer PJ 2007 Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:190-195 (Pubitemid 46067530)
31. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ 2001 Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab 86:3304-3310 (Pubitemid 32673502)
32. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM 2001 The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 86:259-266 (Pubitemid 32109805)
33. Anniko M, Wersäll J 1982 Morphological effects in pituitary tumours following radiotherapy. Virchows Arch A Pathol Anat Histol 395:45-58 (Pubitemid 12132516)
34. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ 2002 Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clin Endocrinol Metab 87:5737-5745 (Pubitemid 36034384)
35. Peng XD, Park S, Gadelha MR, Coschigano KT, Kopchick JJ, Frohman LA, Kineman RD 2001 The growth hormone (GH)-axis of GH receptor/binding protein gene-disrupted and metallothioneinhuman GH-releasing hormone transgenic mice: hypothalamic neuropeptide and pituitary receptor expression in the absence and presence of GH feedback. Endocrinology 142:1117-1123 (Pubitemid 32202821)
36. Asa SL, Coschigano KT, Bellush L, Kopchick JJ, Ezzat S 2000 Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. Am J Pathol 156:1009-1015 (Pubitemid 30626958)
37. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ, Ezzat S 2007Agrowth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67:7505-7511
38. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M 2001 Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 86:5194-5200 (Pubitemid 33070235)
39. Ezzat S, Asa SL, Stefaneanu L, Whittom R, Smyth HS, Horvath E, Kovacs K, Frohman LA 1994 Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. J Clin Endocrinol Metab 78:555-560 (Pubitemid 24083291)
40. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ 1988 Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040-1048
41. Sautner D, Saeger W, Tallen G, Lüdecke DK, Rehpenning W 1993 Effects of octreotide on morphology of pituitary adenomas in acromegaly. Pathol Res Pract 189:1044-1051 (Pubitemid 23363279)
42. Ben-Shlomo A, Melmed S 2008 Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286:192-198
43. Ronchi CL, Rizzo E, Lania AG, Pivonello R, Grottoli S, Colao A, Ghigo E, Spada A, Arosio M, Beck-Peccoz P 2008 Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 158:19-25 (Pubitemid 351211036)
44. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D 2007 Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592-1599 (Pubitemid 46997156)
45. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD 2006 Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29:826-830 (Pubitemid 44872594)
46. Matsuno A, Katakami H, Sanno N, Ogino Y, Osamura RY, Matsukura S, Shimizu N, Nagashima T 1999 Pituitary somatotroph adenoma producing growth hormone (GH)-releasing hormone (GHRH) with an elevated plasma GHRH concentration: a model case for autocrine and paracrine regulation of GH secretion by GHRH. J Clin Endocrinol Metab 84:3241-3247 (Pubitemid 30646951)
47. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM 2008 The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14:6364-6370
48. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R 2009 Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623
49. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A 2002 In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21:8240-8250